Pfizer (NYSE: PFE) has initiated cost-reduction strategies while exceeding quarterly profit forecasts despite an 8% sales decline due to waning Covid-related revenue. The company aims for $4.5B in savings by 2025, maintaining its 2025 sales guidance of $61B-$64B amidst uncertainty.